Imperial College London
Portrait Picture

Simon Erridge

Faculty of Medicine, Department of Surgery & Cancer

Research Postgraduate
 
 
 
//

Contact

 

simon.erridge12

 
 
//

Location

 

Block B Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Mangoo:2023:10.1080/14737175.2022.2161894,
author = {Mangoo, S and Erridge, S and Holvey, C and Coomber, R and Barros, DAR and Bhoskar, U and Mwimba, G and Praveen, K and Symeon, C and Sachdeva-Mohan, S and Rucker, JJ and Sodergren, MH},
doi = {10.1080/14737175.2022.2161894},
journal = {Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders},
pages = {995--1008},
title = {Assessment of clinical outcomes of medicinal cannabis therapy for depression: analysis from the UK Medical Cannabis Registry},
url = {http://dx.doi.org/10.1080/14737175.2022.2161894},
volume = {22},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundAlthough pre-clinical experiments associate cannabinoids with reduced depressive symptoms, there is a paucity of clinical evidence. This study aims to analyze the health-related quality of life changes and safety outcomes in patients prescribed cannabis-based medicinal products (CBMPs) for depression.MethodsA series of uncontrolled cases from the UK Medical Cannabis Registry were analyzed. The primary outcomes were changes from baseline in the Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), Sleep Quality Scale (SQS), and EQ-5D-5 L at 1, 3, and 6 months. Secondary outcomes included adverse events incidence.Results129 patients were identified for inclusion. Median PHQ-9 at baseline was 16.0 (IQR: 9.0–21.0). There were reductions in PHQ-9 at 1-month (median: 8.0; IQR: 4.0–14.0; p < 0.001), 3-months (7.0; 2.3–12.8; p < 0.001), and 6-months (7.0; 2.0–9.5; p < 0.001). Improvements were also observed in GAD-7, SQS, and EQ-5D-5L Index Value at 1, 3, and 6 months (p < 0.050). 153 (118.6%) adverse events were recorded by 14.0% (n = 18) of participants, 87% (n = 133) of which were mild or moderate.ConclusionCBMP treatment was associated with reductions in depression severity at 1, 3, and 6 months. Limitations of the study design mean that a causal relationship cannot be proven. This analysis provides insights for further study within clinical trial settings.
AU  - Mangoo,S
AU  - Erridge,S
AU  - Holvey,C
AU  - Coomber,R
AU  - Barros,DAR
AU  - Bhoskar,U
AU  - Mwimba,G
AU  - Praveen,K
AU  - Symeon,C
AU  - Sachdeva-Mohan,S
AU  - Rucker,JJ
AU  - Sodergren,MH
DO  - 10.1080/14737175.2022.2161894
EP  - 1008
PY  - 2023///
SN  - 1473-7175
SP  - 995
TI  - Assessment of clinical outcomes of medicinal cannabis therapy for depression: analysis from the UK Medical Cannabis Registry
T2  - Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders
UR  - http://dx.doi.org/10.1080/14737175.2022.2161894
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000905941300001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
UR  - https://www.tandfonline.com/doi/full/10.1080/14737175.2022.2161894
UR  - http://hdl.handle.net/10044/1/101579
VL  - 22
ER  -
Download